Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes (Nasdaq:ALKS) will present 26 sleep-medicine abstracts at SLEEP 2026 in Baltimore, June 14–17, 2026. Highlights include detailed positive phase 2 Vibrance-2 data on investigational OX2R agonist alixorexton in narcolepsy type 2, and multiple studies of once-nightly LUMRYZ (sodium oxybate).
Presentations span phase 2 and phase 3 trial designs (Brilliance, REVITALYZ), real‑world LUMRYZ evidence (REFRESH), claims analyses on hypersomnolence disorders, and patient survey data on fatigue, cognition, and treatment preferences. LUMRYZ prescribing information emphasizes CNS depression, abuse/misuse risks, and REMS distribution requirements.
Alkermes (Nasdaq: ALKS) will join the Goldman Sachs 47th Annual Global Healthcare Conference, with a fireside chat on June 10, 2026 at 10:00 a.m. ET. A live webcast will be available via the Investors tab on Alkermes’ website and archived for 14 days.
Alkermes is a global biopharma company focused on neuroscience, with commercial products and late-stage pipeline candidates for addiction, psychiatric, sleep, and neurological disorders.
Alkermes (Nasdaq: ALKS) will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting, May 26-29, 2026, in Miami.
Data span LYBALVI, ARISTADA, and investigational orexin 2 receptor agonists (alixorexton, ALKS 4510, ALKS 7290), covering schizophrenia, bipolar I disorder, narcolepsy, and idiopathic hypersomnia.
Alkermes (Nasdaq: ALKS) is presenting new clinical and real-world evidence for LYBALVI and ARISTADA at multiple spring 2026 psychiatry and health economics conferences. Key data cover LYBALVI’s impact on adherence, persistence, relapse proxies, hospitalizations and ER visits, including in young adults, plus long-acting injectable use in schizophrenia and sleep-disorder burden research.
The announcement also reiterates LYBALVI’s U.S. indications for adult schizophrenia and bipolar I disorder and highlights important safety information, including a boxed warning for dementia-related psychosis and contraindication with opioid use or acute opioid withdrawal.
Alkermes (Nasdaq: ALKS) reported positive topline results from the phase 3 REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia. LUMRYZ met the primary ESS endpoint and key secondary PGI-C and IHSS endpoints (all p<0.0001) versus placebo, with a safety profile consistent with prior data. Alkermes plans to file an sNDA by end of 2026 but cannot market LUMRYZ for IH before March 1, 2028.
Alkermes (Nasdaq: ALKS) reported financial results for the quarter ended March 31, 2026 and provided financial expectations for full year 2026. The company will discuss results on a live conference call and webcast at 8:00 a.m. ET / 1:00 p.m. BST on May 5, 2026.
Investors can access the webcast and replay, and find the detailed earnings release and presentation, on Alkermes' investor relations website.
Alkermes (Nasdaq: ALKS) will report first quarter 2026 financial results and host a conference call and webcast on May 5, 2026 at 8:00 a.m. ET (1:00 p.m. BST). The webcast and slides will be available on the company website; a replay will be posted about two hours after the event.
Dial-in numbers are provided for U.S. and international callers; investor relations contact: Sandy Coombs, +1 781 609 6377.
Alkermes (Nasdaq: ALKS) will present new Vibrance-1 phase 2 data for alixorexton at AAN 2026 showing clinically meaningful, statistically significant improvements in wakefulness, cognition and fatigue in NT1 patients. The 92-patient trial included a six-week randomized period plus a seven-week open-label extension; >95% completed 13 weeks.
No serious treatment-emergent adverse events were reported; phase 3 Brilliance NT1 study is ongoing and alixorexton holds FDA Breakthrough Therapy designation for NT1.
Alkermes (Nasdaq: ALKS) announced publication of a 56-week post hoc analysis in The Journal of Clinical Psychiatry showing LYBALVI (olanzapine and samidorphan) was associated with sustained reductions in negative symptoms of schizophrenia over 56 weeks.
Key results: PANSS Negative Subscale LS mean change −7.6 and Marder Negative Factor −8.2 at week 56 (n=281 completers).
Alkermes (Nasdaq: ALKS) initiated the Phase 3 Brilliance Studies of alixorexton, an oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 and type 2 on April 1, 2026. The program comprises three 12-week, randomized, double-blind, placebo-controlled studies testing once-daily and split-dose regimens.
Primary endpoints measure wakefulness by mean sleep latency on the MWT; secondary endpoints include ESS, weekly cataplexy rate, patient-reported outcomes, safety, and long-term open-label follow-up eligibility.